‘Argus lowered the firm’s price target on Colgate-Palmolive (CL) to $104 from $112 but keeps a Buy rating on the shares. The firm has a favorable view of the company’s products with natural ingredients and of its new pet foods for younger pets and for older pets with kidney problems, while the stock’s post-earnings recent price weakness provides a buying opportunity, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CL:
- Colgate-Palmolive’s Strategic Initiatives and Market Position Reinforce Buy Rating Despite Challenges
- Colgate-Palmolive price target lowered to $105 from $110 at Raymond James
- Colgate-Palmolive price target lowered to $100 from $105 at Evercore ISI
- Colgate-Palmolive price target lowered to $93 from $95 at Stifel
- Colgate-Palmolive price target lowered to $104 from $111 at Morgan Stanley